Functional precision cancer medicine-moving beyond pure genomics
Functional precision cancer medicine-moving beyond pure genomics
复制标题
DOI：
10.1038/nm.4389
复制
发表时间：
2017-09-01
期刊：
影响因子：
82.9
通讯作者：
Letai, Anthony
中科院分区：
文献类型：
--
作者：
Letai, Anthony
精准医疗的基本工作是为合适的病人配上合适的药物。在癌症领域，精准医疗几乎等同于基因组学。然而，最近发人深省的研究普遍表明，大多数接受基因组检测的癌症患者并没有从基因组精准医学策略中受益。尽管有些人对整个精准癌症医学项目提出质疑，但我建议必须扩大所使用的工具。我们不应该完全依赖于初始条件的大数据测量，我们还应该通过扰动获得高度可操作的功能信息，例如，通过癌症治疗，从癌症患者身上获得可存活的原发肿瘤细胞。
The essential job of precision medicine is to match the right drugs to the right patients. In cancer, precision medicine has been nearly synonymous with genomics. However, sobering recent studies have generally shown that most patients with cancer who receive genomic testing do not benefit from a genomic precision medicine strategy. Although some call the entire project of precision cancer medicine into question, I suggest instead that the tools employed must be broadened. Instead of relying exclusively on big data measurements of initial conditions, we should also acquire highly actionable functional information by perturbing-for example, with cancer therapies-viable primary tumor cells from patients with cancer.